Puma Biotechnology Inc

Puma Biotechnology Inc

NNASDAQ:PBYI
7.34
USD
-0.43
(-5.53%)
0.46EPS
21.22P/E
513.27MMarket Cap
Mar 04Next Earn
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
- -
- -
- -
- -
0.74
6.62
7.02
5.69
6.23
5.1
5
4.74
4.57
4.55
Basic EPS, GAAP
-1.9
-4.73
-7.45
-8.29
-7.85
-2.99
-1.95
-1.52
-0.72
- -
0.46
0.62
0.62
0.47
Free Cash Flow per Basic Share
-1.94
-2.62
-4.84
-4.47
-6
-0.65
0.57
-0.23
0.51
-0.51
0.3
0.8
0.83
0.9
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
2.9
3.83
6.35
5.7
1.42
0.9
0.45
-0.15
-0.06
0.47
1.12
1.88
2.59
2.84
Tangible Book Value per Share
2.9
3.83
6.35
5.7
0.13
-0.26
-0.59
-2
-1.67
-1.06
-0.16
0.83
1.76
2.18
Basic Weighted Avg Shares
29
30
32
33
37
38
39
40
41
45
47
49
50
51
Sales/Revenue/Turnover
- -
- -
- -
- -
28
251
272
225
253
228
236
230
228
232
Operating Margin (%)
- -
- -
- -
- -
-1,056.13
-37.71
-14.34
-13.51
0.51
13.47
13.85
13.44
16.33
11.27
Depreciation Expense
- -
1
1
1
3
7
8
10
11
10
12
12
11
10
Net Income, GAAP
-55
-142
-239
-276
-292
-114
-76
-60
-29
- -
22
30
31
24
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
99.56
4.78
- -
13.05
15.19
Profit Margin (%)
- -
- -
- -
- -
-1,054.56
-45.25
-27.77
-26.65
-11.51
- -
9.16
13.14
13.62
10.28
Working Capital
77
105
191
199
48
136
75
32
30
57
57
52
81
106
LT Debt
- -
- -
- -
- -
48
152
118
104
113
110
73
23
5
4
Total Equity
84
117
206
210
53
34
17
-6
-2
22
53
92
130
147
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
0.08
20.72
- -
19.97
14.4
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
0.04
22.79
- -
22.68
16.6
Return on Common Equity (%)
-51.35
-141.23
-148.14
-132.75
-221.91
-259.28
-292.05
- -
- -
- -
57.54
41.6
27.97
18.2

Capital Structure

USD

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
ST Debt
11
- -
1
LT Borrowings
- -
- -
- -
LT Finance Leases
5
4
4
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
51
51
52
Market Capitalization
325
414
513

Working Capital

USD

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
Total Current Assets
142
145
158
Cash, Cash Equivalents & STI
102
94
109
Accounts Receivable, Net
26
34
33
Inventories
9
13
11
Total Current Liabilities
60
50
52
Payables & Accruals
39
39
39
ST Debt
11
- -
1
Deferred Revenue
- -
- -
- -

Growth Rates

USD

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
-107.27%
-156.22%
41.48%
Free Cash Flow
-89.32%
-103.67%
7.38%
Net Income, GAAP
107,924.75%
215,868.3%
2.75%
Sales/Revenue/Turnover
- -
0.56%
-0.91%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
44
47
81
59
230
2025
46
52
54
75
228
2026
45
57
55
- -
- -

Quarterly Earnings Per Share

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-0.1
-0.09
0.41
0.39
0.62
2025
0.06
0.12
0.18
0.27
0.62
2026
-0.07
0.16
0.12
- -
- -

Quarterly Dividends Per Share

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Company Description

CEO
Alan H. Auerbach
Full Time Employees
179
Sector
Health technology
Industry
Pharmaceuticals: major
Address
10880 Wilshire Boulevard Los Angeles CA United States 90024
IPO Date
Mar 21, 2012
Business
Puma Biotechnology, Inc. is a biopharmaceutical company focused on the development and commercialization of innovative cancer therapeutics. Its primary products include NERLYNX® (neratinib), a potent irreversible tyrosine kinase inhibitor for the extended adjuvant treatment of adult patients with early-stage HER2-positive breast cancer, approved by the U.S. FDA and marketed in the United States since 2017. NERLYNX is also approved for combination treatment in advanced or metastatic HER2-positive breast cancer and authorized in the European Union and multiple international regions including Canada, Latin America, Greater China, Israel, Southeast Asia, Australia, New Zealand, South Korea, the Middle East, and parts of Africa. Puma also develops alisertib, an orally administered, selective inhibitor of aurora kinase A, targeting metastatic breast cancer and other cancers. The company in-licenses drug candidates and pursues clinical development to expand product indications. Founded in 2010 and headquartered in Los Angeles, California, Puma Biotechnology has recently reported an 8% increase in U.S. NERLYNX sales and ongoing clinical trials with interim data for alisertib expected in late 2025. It has expanded commercialization partnerships notably in Eastern Europe and Central Asia and secured financial backing through note purchase agreements to support its commercial and R&D activities. The company remains focused on enhancing cancer care by advancing its flagship product NERLYNX and expanding its oncology pipeline with alisertib and other in-licensed candidates.

Company News

  • Puma: 3 Key Takeaways for Long-Term Investors

  • Puma Biotechnology, Inc. (PBYI) Q3 2026 Earnings Call Prepared Remarks Transcript

  • Puma Biotechnology Q3 Earnings Call Highlights

  • Puma Biotechnology Reports Third Quarter 2026 Financial Results

  • Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

  • Puma Biotechnology to Host Conference Call to Discuss Third Quarter 2026 Financial Results

  • Will Nerlynx Continue to Aid Puma Biotechnology's Top Line in Q3?

  • 4 Breast Cancer Stocks to Watch During Breast Cancer Awareness Month

  • Puma Biotechnology Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4)

  • Comparing TG Therapeutics (NASDAQ:TGTX) and Puma Biotechnology (NASDAQ:PBYI)

  • PBYI's Alisertib Combo Phase II Study in Small Cell Lung Cancer Begins

  • Puma Biotechnology Initiates ALISCA®-Lung2, a Phase II Trial of Alisertib in Combination with Paclitaxel for the Treatment of Patients with Advanced Small Cell Lung Cancer

  • Puma Biotechnology to Present at H.C. Wainwright's 28th Annual Global Investment Conference

  • Puma Biotechnology: NERLYNX Funds Their Potential Next Oncology Franchise

  • Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

  • 3,804,736 Shares in Puma Biotechnology, Inc. $PBYI Bought by BlackRock Inc.

  • Is Puma Biotechnology (PBYI) a Great Value Stock Right Now?

  • PBYI Q2 Earnings & Sales Beat Estimates, 2026 Guidance Raised

  • Puma Biotechnology, Inc. (PBYI) Q2 2026 Earnings Call Transcript

  • Puma Biotechnology Q2 Earnings Call Highlights